Are GLP-1s miracle drugs? Dr. Oz weighs in | Elizabeth Vargas Reports

What happened in this episode?

Dr. Mehmet Oz, serving as one of the President's top medical advisers, announced a landmark federal program making GLP-1 weight loss medications available to Medicare beneficiaries for $50 per month, beginning the day before this interview. The initiative, enabled through most favored nation drug pricing negotiations, aims to expand access to medications like Ozempic and Wegovy beyond affluent Americans to address nationwide obesity and chronic illness. Oz revealed that thousands enrolled overnight without technical glitches and estimates millions will ultimately gain access. The program represents an 18-month pilot to measure demand among Americans seeking weight loss assistance, not just those with existing conditions like heart disease or diabetes who already qualify for coverage. Oz emphasized that approximately 70% of all healthcare spending stems from chronic illnesses related to weight, arguing the program could generate taxpayer savings by reducing downstream medical complications. He noted that previously these medications were disproportionately used in wealthy areas like Manhattan's Upper East Side rather than communities with greatest medical need. The discussion covered the broader benefits of GLP-1 drugs beyond appetite suppression, which Oz described as having side benefits still being discovered. He stressed the administration's goal of making these medications affordable to all Americans rather than remaining accessible only to the affluent, positioning the initiative as both a public health intervention and fiscal strategy.

What are the key points?

• Dr. Mehmet Oz announced Medicare beneficiaries can now access GLP-1 weight loss drugs for $50 monthly through new federal program
• The initiative launched yesterday using most favored nation drug pricing negotiations to reduce costs from unaffordable levels
• Thousands enrolled overnight in the program available at Trump.RX.gov with no technical issues reported during rollout
• Oz estimates millions of Medicare recipients will ultimately gain access to medications previously limited to wealthy Americans
• Medicare already covers GLP-1 drugs for patients with heart disease, diabetes, and other conditions; new program adds weight loss eligibility
• The 18-month pilot program aims to measure American appetite for using GLP-1 medications purely for weight reduction
• Oz stated 70% of healthcare spending stems from weight-related chronic illness, projecting taxpayer savings from preventive intervention

Which topics are covered?

How is this page sourced?

Programme

Reality Check with Ross Coulthart

Published

3 July 2026

Duration

5m

Original episode

Open the original source ↗

Egleze verifies the speaker, source and timestamp for each linked moment. Unless a moment is explicitly marked independently verified, statements remain attributed claims by the named speaker rather than established facts.